MUC1号
癌症研究
下调和上调
三阴性乳腺癌
免疫系统
跨膜蛋白
粘蛋白
PD-L1
免疫检查点
发病机制
免疫学
乳腺癌
癌症
生物
免疫疗法
抗原
医学
受体
病理
内科学
遗传学
基因
作者
Takahiro Maeda,Masayuki Hiraki,Caining Jin,Hasan Rajabi,Ashujit Tagde,Maroof Alam,Audrey Bouillez,Xiufeng Hu,Yozo Suzuki,Masaaki Miyo,Tsuyoshi Hata,Kunihiko Hinohara,Donald Küfe
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2017-12-20
卷期号:78 (1): 205-215
被引量:194
标识
DOI:10.1158/0008-5472.can-17-1636
摘要
The immune checkpoint ligand PD-L1 and the transmembrane mucin MUC1 are upregulated in triple-negative breast cancer (TNBC), where they contribute to its aggressive pathogenesis. Here, we report that genetic or pharmacological targeting of the oncogenic MUC1 subunit MUC1-C is sufficient to suppress PD-L1 expression in TNBC cells. Mechanistic investigations showed that MUC1-C acted to elevate
科研通智能强力驱动
Strongly Powered by AbleSci AI